title: Cardiovascular Effects of the New Weight Loss Agents.
abstract: The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
authors.affiliation: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York.
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Vorsanger
authors.affiliation: Division of General Internal Medicine, Department of Medicine, The Mount Sinai Hospital, New York, New York.
authors.forename: Pritha
authors.initials: P
authors.lastname: Subramanyam
authors.affiliation: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York.
authors.forename: Howard S
authors.initials: HS
authors.lastname: Weintraub
authors.affiliation: Division of General Internal Medicine, Department of Medicine, New York University Langone Medical Center, New York, New York.
authors.forename: Steven H
authors.initials: SH
authors.lastname: Lamm
authors.affiliation: Division of General Internal Medicine, Department of Medicine, New York University Langone Medical Center, New York, New York.
authors.forename: James A
authors.initials: JA
authors.lastname: Underberg
authors.affiliation: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Gianos
authors.affiliation: Department of Medicine, Division of Endocrinology, New York University Langone Medical Center, New York, New York.
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Goldberg
authors.affiliation: Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York. Electronic address: arthur.schwartzbard@nyumc.org.
authors.forename: Arthur Z
authors.initials: AZ
authors.lastname: Schwartzbard
mesh_terms: D019440:Anti-Obesity Agents / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008019:Life Style; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D019440:Anti-Obesity Agents
keywords: cardiovascular disease; obesity; pharmacology; prevention; risk factors